A study of the safety and toxicity of the combination of zoledronic acid, fluvastatin and everolimus given to patients with advanced cancer

Trial Profile

A study of the safety and toxicity of the combination of zoledronic acid, fluvastatin and everolimus given to patients with advanced cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Everolimus (Primary) ; Fluvastatin; Zoledronic acid
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top